Evaluation of Whether the Selective Progesterone Receptor Modulator CDB-2914 Can Shrink Leiomyomata
25 Years
50 Years
Female
Leiomyoma
Trial Information
Evaluation of Whether the Selective Progesterone Receptor Modulator CDB-2914 Can Shrink Leiomyomata
Uterine leiomyomata (fibroids) are a common benign tumor of the uterine muscle in
pre-menopausal women that may cause bleeding, pelvic pain and pressure. Because fibroids
grow in the presence of estrogen, medical therapies that decrease estrogen levels (like
Gonadotropin releasing hormone,GnRH analog) cause fibroids to shrink and so may relieve
symptoms. However, such medication can only be given short-term and has inconvenient side
effects such as hot-flashes. Thus, many women with symptomatic fibroids choose to have them
removed surgically, either individually or by removing the uterus via hysterectomy.
Women between 25 and 50 years of age who have regular menstrual cycles and a history of
uterine fibroids that cause heavy bleeding, pressure, or pain may be eligible for this
study. Candidates are screened with a medical history and physical examination, including
breast and pelvic examination, blood and urine tests, a quality-of-life questionnaire, and a
home urine test for leuteinizing hormone (LH) surge. They are given a diary to record the LH
surge, days of vaginal spotting or bleeding, and symptoms. Participation includes the
following:
Baseline Studies (First Menstrual Cycle)
- Magnetic resonance imaging (MRI): The subject lies in the MRI scanner, a narrow
cylinder with a strong magnetic field, for imaging the uterus.
- Saline hysterosonogram: This is an ultrasound examination of the uterus. A speculum is
placed in the vagina and a small amount of liquid is inserted into the uterus. A probe
is then inserted into the vagina. The probe emits and receives sound waves that are
used to visualize the fibroids and surrounding structures.
Study Drug Phase (Second through Fourth Menstrual Cycles)
- Subjects are randomly assigned to take ulipristal acetate or placebo (inactive
compound) once a day by mouth on an empty stomach for three menstrual cycles or up to
102 days if menstrual cycles are irregular or stop.
- Pregnancy test on first or second day of every menstrual cycle.
- Blood tests every 2 weeks to measure effects of study medication on hormones, blood
count, blood chemistries and liver function.
- 24-hour urine collections three times during the study, about once a month, to measure
cortisol and check adrenal gland function.
- Repeat transvaginal ultrasound after 4-6 weeks of study drug to check fibroid growth.
- Repeat hysterosonogram and MRI within 2 weeks of surgery to count and measure the
fibroids. or placebo (inactive compound) once a day by mouth on an empty stomach for
three menstrual cycles or up to 102 days if menstrual cycles are irregular or stop.
- Pregnancy test on first or second day of every menstrual cycle.
- Blood tests every 2 weeks to measure effects of study medication on hormones, blood
count, blood chemistries and liver function.
- 24-hour urine collections three times during the study, about once a month, to measure
cortisol and check adrenal gland function.
- Repeat transvaginal ultrasound after 4-6 weeks of study drug to check fibroid growth.
- Repeat hysterosonogram and MRI within 2 weeks of surgery to count and measure the
fibroids. or placebo (inactive compound) once a day by mouth on an empty stomach for
three menstrual cycles or up to 102 days if menstrual cycles are irregular or stop.
- Pregnancy test on first or second day of every menstrual cycle.
- Blood tests every 2 weeks to measure effects of study medication on hormones, blood
count, blood chemistries and liver function.
- 24-hour urine collections three times during the study, about once a month, to measure
cortisol and check adrenal gland function.
- Repeat transvaginal ultrasound after 4-6 weeks of study drug to check fibroid growth.
- Repeat hysterosonogram and MRI within 2 weeks of surgery to count and measure the
fibroids.
Inclusion Criteria
INCLUSION CRITERIA:
- Female gender-to evaluate effects in the target population for clinical trials.
- History of uterine leiomyoma causing symptoms of bleeding, pressure, or pain, as
defined by the American College of Obstetrics and Gynecology (ACOG) practice
bulletin:
- Excessive uterine bleeding will be evidenced by either of the following-profuse
bleeding with flooding or clots or repetitive periods lasting for more than 8 days;
or anemia due to acute or chronic blood loss;
OR
- Pelvic discomfort caused by leiomyomata, either acute and severe or chronic lower
abdominal or low back pressure or bladder pressure with urinary frequency not due to
urinary tract infection.
- Uterine leiomyoma(ta) of at least 2 cm size.
- In good health. Chronic medication use is acceptable except for glucocorticoid use.
Other chronic medication use may be acceptable at the discretion of the research
team. Interval use of over-the-counter drugs is acceptable but must be recorded.
- Menstrual cycles of 24 - 35 days.
- Hemoglobin greater than 10 g/dL (for those wishing surgery); iron may be administered
to improve red blood cell counts.
- Willing and able to comply with study requirements.
- Age 25 to 50.
- Using mechanical (condoms, diaphragms) sterilization or abstinence methods of
contraception for the duration of the study.
- Negative urine pregnancy test.
- Body mass index (BMI) less than or equal to 33, if a surgical candidate or less than
or equal to 35, if not a surgical candidate.
- Creatinine less than 1.3 mg/dL.
- Liver function tests within 130% of upper limit.
- If interested in hysterectomy, no desire for fertility.
EXCLUSION CRITERIA:
- Significant abnormalities in the history, physical or laboratory examination.
- Pregnancy.
- Lactation.
- Use of oral, injectable or inhaled glucocorticoids or megestrol within the last year.
- Unexplained vaginal bleeding.
- History of malignancy within the past 5 years.
- Use of estrogen or progesterone-containing compounds, such as oral contraceptives and
hormone replacement therapy, within 8 weeks of study entry, including transdermal,
injectable, vaginal and oral preparations.
- Use of agents known to induce hepatic P450 enzymes; use of imidazoles.
- Current use of Gonadotropin-releasing hormone (GnRH) analogs or other compounds that
affect menstrual cyclicity.
- Follicle stimulating hormone (FSH) greater than 20 IU/mL.
- Untreated cervical dysplasia.
- Need for interval use of narcotics.
- Abnormal adnexal/ovarian mass.
- Use of herbal medication having estrogenic or antiestrogenic effects within the past
3 months.
- Contradiction to anesthesia, for women planning surgery.
- Genetic causes of leiomyomata.
- Previous participation in the study.
- Known recent rapid growth of fibroids, defined as a doubling in size in six months.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Outcome Measure:
Shrinkage of Fibroids - Size of Fibroids
Outcome Description:
The primary outcome, fibroid volume, was calculated by an ellipsoid formula (π/6xd1xd2xd3) using orthogonal three-dimensional measurements taken from pelvic MRI scan. Individual volumes were summed to assess total fibroid volume for each woman, which were log-transformed before analysis. Women with paired MRI results were included in this intent to treat analysis, even if they did not take all study medication. Fibroids were included if they were seen on both studies.The absolute change in cm3 between baseline and end of treatment was calculated and its log was used for statistics and reporting the results in the data table below.
Outcome Time Frame:
3 months (baseline to end of treatment)
Safety Issue:
No
Principal Investigator
Lynnette K Nieman, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
NICHD, NIH
Authority:
United States: Food and Drug Administration
Study ID:
060090
NCT ID:
NCT00290251
Start Date:
February 2006
Completion Date:
August 2010
Related Keywords:
- Leiomyoma
- Endometrium
- Progesterone
- Estrogen
- Fibroid
- Hysterectomy
- Leiomyoma
- Uterine Fibroids
- Fibroids
- Leiomyoma
- Myofibroma
Name | Location |
|---|---|
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda, Maryland 20892 |
| NIH Clinical Center | Bethesda, Maryland 20892 |
